About the Company
Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ADRO News
Pharmala Biotech Holdings Inc MDMA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Krystal Biotech Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Best Biotech Penny Stocks
Looking for the best biotech penny stocks? The most important innovation of the 1990s was the internet — today, it would be a vaccine for COVID-19. If these times have anything to say about it ...
5 Best-Performing Biotech Stocks for May 2024
NerdWallet, Inc. does not offer advisory or brokerage ... but the need for medicine will never go away. Biotech stocks give investors a way to potentially earn profits while funding the industry ...
Nascent Biotech, Inc. (NBIO)
NORTH PALM BEACH, FL / ACCESSWIRE / April 16, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage ...
Krystal Biotech moves to next step in clinical trial
Krystal Biotech has announced the first patient has joined a trial for its inhaled treatment for a solid lung cancer tumor.
NKGen Biotech Inc NKGN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Edesa Biotech, Inc. (EDSA)
Revolving Line of Credit to Support Completion of Government-Funded ARDS StudyTORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa", or the "Company"), a ...
Oncolytics Biotech Inc.
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of ...
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call Transcript
Moleculin Biotech, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, welcome to the Moleculin Biotech 2023 ...
KRYS Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes ...
KRYS Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes ...
Loading the latest forecasts...